Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Greenphire and IMS Health Announce Strategic Integration

Published: Friday, June 21, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Launch of strategic integration of eClinicalGPS and GrantPlan.

Greenphire has announced the launch of a strategic integration of Greenphire’s eClinicalGPS, the leading global investigator payment technology, with IMS Health’s GrantPlan, the leading benchmarking and contracting tool for global clinical site grants.

Together, the two technologies will enable the companies’ clients to access valuable analytics that have previously not been available or near impossible to aggregate.

Clients will be able to compare benchmarked data against both actual contracted amounts and actual expenses incurred, and precisely evaluate the performance of third parties responsible for negotiating contracts.

Clients will also be able to proactively identify and mitigate unplanned expenses throughout a specific study and to better anticipate actual budget variance in future trials.

The product integration will also allow for a quick and easy transition from the planning and contracting phase of a clinical trial to the trial’s execution by automating data-sharing throughout the clinical financial lifecycle.

For site contracting processes, data will seamlessly flow in a closed loop from the benchmarking and planning phase, to the contracting and negotiation phase, through to the execution of payments to sites and payment data aggregation for the purposes of Sunshine Act and other required reporting.

Linda Drumright, General Manager of Clinical Trial Optimization Solutions at IMS Health, said, “This collaboration with Greenphire will build an integration between two of the industry’s leading clinical financial technologies, enabling sponsors to gain further control over the costs associated with clinical trials, from budgeting and planning to payment execution, and to automatically access the information they need to keep their trials on track and remain compliant with global regulations.”

“We are very excited to launch this integration with IMS Health’s GrantPlan to drive additional value for our respective clients,” said Greenphire Founder & CEO Sam Whitaker, “Our combined technologies will provide clinical trial managers with the tools they need to stay informed about how actual study expenses are lining up with budgets, in real-time, and accurately project future expenses against budgets. We are striving to not only further automate the contracting, negotiation and payment management environment, but also equip our clients with the data needed to make informed decisions that will enable them to course-correct and take action in the present to control costs at future points in time.”

IMS Health’s GrantPlan is the industry’s leading benchmarking tool for current global clinical grant costs. It is the world’s largest database of such costs, containing extensive cost data at the cost per procedure, cost per visit, and cost per patient levels from around the world, including emerging countries.

IMS Health’s GrantPlan is the most recognized product representing current fair market value for investigator grant costs and is the world’s first 100% web-based online benchmarking and negotiation tool for international clinical grants.

Greenphire’s eClinicalGPS facilitates accurate payment calculation, manages complex payment approval processes, and automates payment execution in local currencies from sponsors and CROs to all investigators, sites and other vendors involved in a clinical trial on a global basis.

Using an intelligent web-based clinical payment platform, the eClinicalGPS dramatically reduces the time and resources needed to calculate, approve and deliver site payments in local currency and produce complex reports, including aggregated reports needed to make disclosures required by the Sunshine Act and other global transparency laws.

The eClinicalGPS turns a historically manual and tactical task‐driven administrative process into an automated process that provides strategic value to Greenphire's clients.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Greenphire Awards $35,000 to Three Health and Wellness Nonprofits
NO MORE received a donation of $20,000 to further its mission to end domestic violence and sexual assault.
Wednesday, June 25, 2014
Greenphire Appoints Senior Director of Business Development in Europe
Alex Livingstone brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company.
Thursday, October 10, 2013
Greenphire Named One of the Fastest-Growing U.S Companies
The company has been ranked in the 2013 Inc. Magazine 500 list of the fastest-growing private companies in the U.S.
Wednesday, August 21, 2013
Greenphire and Ernst & Young Announce Strategic Partnership
Partnership will combine eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young.
Wednesday, July 10, 2013
Greenphire and Oracle to Work Together
New partnership to automate clinical trial planning, budgeting and payments.
Tuesday, June 25, 2013
Greenphire's John Samar Named CFO of the Year Finalist
The Philadelphia Business Journal awards honour professionals who have displayed outstanding performance in their roles as corporate financial leaders.
Wednesday, May 29, 2013
Greenphire CEO Selected as Finalist in Ernst & Young Awards
CEO Sam Whitaker has been selected as a finalist for the Ernst & Young Entrepreneur of the Year Awards 2013 in the Greater Philadelphia region.
Friday, May 17, 2013
Greenphire Announces New London Office
Plans to facilitate expansion in Europe.
Tuesday, May 07, 2013
Greenphire Appoints UK-based Global Product Manager
Appointment of Rory O’Hare to facilitate European growth.
Thursday, February 21, 2013
Greenphire Supports Proposed EU Legislation to Reduce Clinical Trial Administration
The proposed legislation expected to be enacted by 2016.
Friday, July 27, 2012
Greenphire Appoints Chief Commercial Officer
Appointment of John M Blakeley to the role of Chief Commercial Officer.
Thursday, July 12, 2012
Greenphire and Merge Healthcare Form Exclusive Partnership
Partnership to integrate clinical payment and EDC platforms.
Wednesday, May 09, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos